New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:00 EDTPACBPacific Biosciences rises 10.9%
Pacific Biosciences is up 10.9%, or 27c, to $2.75
News For PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2015
07:27 EDTPACBPacific Biosciences price target raised to $11 from $9 at Cantor
Subscribe for More Information
October 6, 2015
12:49 EDTPACBIllumina plummets after 2H15 revenue forecast trails estimates
Shares of Illumina (ILMN), which produces tools for genetic analysis, are sinking after the company forecast lower than expected revenue for the third and fourth quarters. Illumina also lowered its fiscal 2015 revenue growth forecast to 18% from 20%. WHAT'S NEW: Illumina yesterday announced preliminary Q3 revenue of approximately $550M, below analysts' consensus estimates of $568.6M. Additionally, the company forecast Q4 revenue of approximately $570M, well below analysts' estimates of $602.83M. Illumina also lowered its forecast for 2015 revenue growth to approximately 18% from its prior view of approximately 20%, including a 3% negative impact from foreign exchange, against analysts' consensus estimates of $2.25B. WHAT'S NOTABLE: Jay Flatley, Illumina's chief executive officer, noted that although the company saw strong demand for sequencing consumables and the HiSeq family of instruments in Q3, instrument sales in the desktop family underperformed company expectations. He said management was "disappointed with instrument sales in Europe and continued weakness in the Asia-Pacific region." Flatley said that the new markets the company is targeting are "enormous," and will support revenue growth for Illumina in 2016 and beyond. The company is expected to provide updated earnings per share guidance on October 20, when the company reports Q3 results. ANALYST REACTION: Sentiment on the Street was mixed at midday. Research firms Mizuho and BTIG downgraded Illumina to Neutral from Buy. In addition, UBS, Stifel, and Cowen all lowered their respective price targets on Illumina shares. Conversely, Piper and Wells Fargo said they would be buyers of Illumina on today's weakness. Another firm, Canaccord, said the Illumina news not all bad and maintained its Buy rating and $250 price target on Illumina shares. PRICE ACTION: In midday trading, Illumina fell $23.17, or about 14.2%, to $140.01 on more than six times its average daily trading volume. Including today's pull back, the shares have lost approximately 14% over the past 12 months. OTHERS TO WATCH: Other companies in the diagnostic business include Affymetrix (AFFX), down 4.1%, HTG Molecular Diagnostics (HTGM), down 4.2%, Quest Diagnostics (DGX), down 3.5%, Pacific Biosciences (PACB), down 2.4%, and Thermo Fisher Scientific (TMO), down 2.7%.
07:23 EDTPACBAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 2, 2015
09:49 EDTPACBPacific Biosciences upgraded to Overweight from Equal Weight at Stephens
October 1, 2015
14:42 EDTPACBPacific Bio new system should help consumable margins, says Piper Jaffray
Subscribe for More Information
05:47 EDTPACBPacific Biosciences to host conference call
Subscribe for More Information
September 30, 2015
17:48 EDTPACBPacific Biosciences launches new sequencing platform
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use